ArticleJournal of the National Cancer Institute2025
Clonal hematopoiesis and subsequent venous thromboembolism among survivors of autologous transplantation for lymphoma.
Article in Journal of the National Cancer Institute, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Clonal Hematopoiesis in Colorectal Cancer: Mechanisms and Implications.Cancer medicine · 2026Review
- Clonal Hematopoiesis (CHIP) in Pulmonary Embolism and CTEPH: Evidence, Mechanisms, and Risk Stratification.International journal of molecular sciences · 2026Review
- Clones and clots in lymphoma transplant survivors.Journal of the National Cancer Institute · 2025Article
Corrections and comments
- Commented on by
Authors and funding
15 authors.
Funding
Abstract
Clonal hematopoiesis is associated with increased risk of venous thromboembolism (VTE). The risk of VTE is high in patients with lymphoma and after autologous peripheral blood stem cell transplantation, and clonal hematopoiesis is present in many patients with lymphoma at autologous peripheral blood stem cell transplantation. We examined whether clonal hematopoiesis increases posttransplant VTE risk in patients with lymphoma. Our study included 557 patients with lymphoma who had survived 2 or more years after receiving autologous peripheral blood stem cell transplantation between 1999 and 2014. Clonal hematopoiesis was measured by targeted sequencing of cryopreserved peripheral blood stem cell product. Median age at stem cell transplantation was 54 years. Subdistribution hazard regression analysis with death as a competing risk was used to examine the association between clonal hematopoiesis in the peripheral blood stem cell product and post-autologous peripheral blood stem cell transplantation VTE. Clonal hematopoiesis was detected in 36.1% of patients. The 8-year cumulative incidence of VTE was 8.2% with clonal hematopoiesis vs 3.6% among patients without clonal hematopoiesis. The presence of PPM1D mutation (hazard ratio = 4.12, 95% CI = 1.55 to 10.92) or TP53 mutation (hazard ratio = 5.31, 95% CI = 1.54 to 18.35), with no clonal hematopoiesis as the referent, was associated with VTE risk in adjusted analysis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.